JP2024091656A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024091656A5 JP2024091656A5 JP2024059450A JP2024059450A JP2024091656A5 JP 2024091656 A5 JP2024091656 A5 JP 2024091656A5 JP 2024059450 A JP2024059450 A JP 2024059450A JP 2024059450 A JP2024059450 A JP 2024059450A JP 2024091656 A5 JP2024091656 A5 JP 2024091656A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody molecule
- virus
- seq
- antibody
- ctla
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18192311.1A EP3617230A1 (en) | 2018-09-03 | 2018-09-03 | Novel antibodies and nucleotide sequences, and uses thereof |
| EP18192311.1 | 2018-09-03 | ||
| JP2021512914A JP7515461B2 (ja) | 2018-09-03 | 2019-09-03 | 新規抗体およびヌクレオチド配列、ならびにそれらの使用 |
| PCT/EP2019/073488 WO2020049001A1 (en) | 2018-09-03 | 2019-09-03 | Novel antibodies and nucleotide sequences, and uses thereof |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021512914A Division JP7515461B2 (ja) | 2018-09-03 | 2019-09-03 | 新規抗体およびヌクレオチド配列、ならびにそれらの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024091656A JP2024091656A (ja) | 2024-07-05 |
| JP2024091656A5 true JP2024091656A5 (cg-RX-API-DMAC10.html) | 2024-12-09 |
| JP7681151B2 JP7681151B2 (ja) | 2025-05-21 |
Family
ID=63490358
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021512914A Active JP7515461B2 (ja) | 2018-09-03 | 2019-09-03 | 新規抗体およびヌクレオチド配列、ならびにそれらの使用 |
| JP2024059450A Active JP7681151B2 (ja) | 2018-09-03 | 2024-04-02 | 新規抗体およびヌクレオチド配列、ならびにそれらの使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021512914A Active JP7515461B2 (ja) | 2018-09-03 | 2019-09-03 | 新規抗体およびヌクレオチド配列、ならびにそれらの使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12291569B2 (cg-RX-API-DMAC10.html) |
| EP (2) | EP3617230A1 (cg-RX-API-DMAC10.html) |
| JP (2) | JP7515461B2 (cg-RX-API-DMAC10.html) |
| KR (1) | KR102866553B1 (cg-RX-API-DMAC10.html) |
| CN (2) | CN119161482A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2019333862B2 (cg-RX-API-DMAC10.html) |
| BR (1) | BR112021003916A2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3111153A1 (cg-RX-API-DMAC10.html) |
| IL (1) | IL281198A (cg-RX-API-DMAC10.html) |
| MX (1) | MX2021002500A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2020049001A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3552615T3 (da) | 2014-07-16 | 2022-02-14 | Transgene | Onkolytisk virus til ekspression af immun-checkpoint-modulatorer |
| TW202321458A (zh) * | 2021-09-22 | 2023-06-01 | 瑞典商生物創新國際公司 | 新穎抗體組合及其用途 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69226871T3 (de) | 1991-06-27 | 2009-09-24 | Bristol-Myers Squibb Co. | CTL4A-Rezeptor, ihn enthaltenden Fusionsproteine und deren Verwendung |
| US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| ES2706547T3 (es) | 1998-12-23 | 2019-03-29 | Pfizer | Anticuerpos monoclonales humanos para CTLA-4 |
| NZ517202A (en) | 1999-08-24 | 2004-05-28 | Medarex Inc | Human CTLA-4 antibodies and their uses |
| EP1528101A1 (en) | 2003-11-03 | 2005-05-04 | ProBioGen AG | Immortalized avian cell lines for virus production |
| FR2884255B1 (fr) | 2005-04-11 | 2010-11-05 | Vivalis | Utilisation de lignees de cellules souches aviaires ebx pour la production de vaccin contre la grippe |
| RU2489486C2 (ru) | 2006-06-20 | 2013-08-10 | Трансжене С.А. | Процесс получения поксвирусов и композиции поксвирусов |
| EP1985305A1 (en) | 2007-04-24 | 2008-10-29 | Vivalis | Duck embryonic derived stem cell lines for the production of viral vaccines |
| AU2008250596C1 (en) | 2007-05-14 | 2010-11-25 | Bavarian Nordic A/S | Purification of Vaccinia virus- and recombinant Vaccinia virus-based vaccines |
| US8357531B2 (en) | 2007-07-03 | 2013-01-22 | Transgene S.A. | Immortalized avian cell lines |
| DK2212345T3 (en) | 2007-11-19 | 2016-03-21 | Transgene Sa | Oncolytic poxvirus vectors |
| AU2009214768B2 (en) | 2008-02-12 | 2015-01-22 | Sanofi Pasteur Limited | Methods using ion exchange and gel filtration chromatography for poxvirus purification |
| SG176554A1 (en) | 2009-05-12 | 2012-01-30 | Transgene Sa | Method for orthopoxvirus production and purification |
| GB201020995D0 (en) * | 2010-12-10 | 2011-01-26 | Bioinvent Int Ab | Biological materials and uses thereof |
| KR102022952B1 (ko) | 2011-08-05 | 2019-09-20 | 신라젠(주) | 백시니아 바이러스의 생산을 위한 방법 및 조성물 |
| EP2912063A1 (en) | 2012-10-23 | 2015-09-02 | Bristol-Myers Squibb Company | Combination of anti-kir and anti-ctla-4 antibodies to treat cancer |
| DK3552615T3 (da) * | 2014-07-16 | 2022-02-14 | Transgene | Onkolytisk virus til ekspression af immun-checkpoint-modulatorer |
| US10196445B1 (en) * | 2015-03-17 | 2019-02-05 | Bristol-Myers Squibb Company | Ipilimumab variant with enhanced ADCC |
| AU2016370648B2 (en) * | 2015-12-15 | 2023-03-09 | OncoC4, Inc. | Chimeric and humanized anti-human CTLA4 monoclonal antibodies and uses thereof |
| US20190241658A1 (en) * | 2016-01-10 | 2019-08-08 | Modernatx, Inc. | Therapeutic mRNAs encoding anti CTLA-4 antibodies |
| NL2017270B1 (en) * | 2016-08-02 | 2018-02-09 | Aduro Biotech Holdings Europe B V | New anti-hCTLA-4 antibodies |
| IL307242B1 (en) | 2016-12-07 | 2026-07-01 | Agenus Inc | Anti-CTLA-4 antibodies and methods of using them |
| IL270743B2 (en) * | 2017-05-19 | 2024-09-01 | Wuxi Biologics Shanghai Co Ltd | Monoclonal antibodies to cytotoxic t-lymphocyte-associated protein 4 (ctla-4), compositions containing same and uses thereof |
-
2018
- 2018-09-03 EP EP18192311.1A patent/EP3617230A1/en not_active Withdrawn
-
2019
- 2019-09-03 CN CN202411416221.7A patent/CN119161482A/zh active Pending
- 2019-09-03 US US17/272,740 patent/US12291569B2/en active Active
- 2019-09-03 CN CN201980055914.9A patent/CN112912398B/zh active Active
- 2019-09-03 CA CA3111153A patent/CA3111153A1/en active Pending
- 2019-09-03 WO PCT/EP2019/073488 patent/WO2020049001A1/en not_active Ceased
- 2019-09-03 JP JP2021512914A patent/JP7515461B2/ja active Active
- 2019-09-03 AU AU2019333862A patent/AU2019333862B2/en active Active
- 2019-09-03 MX MX2021002500A patent/MX2021002500A/es unknown
- 2019-09-03 BR BR112021003916-3A patent/BR112021003916A2/pt unknown
- 2019-09-03 KR KR1020217009505A patent/KR102866553B1/ko active Active
- 2019-09-03 EP EP19761869.7A patent/EP3847193A1/en active Pending
-
2021
- 2021-03-02 IL IL281198A patent/IL281198A/en unknown
-
2024
- 2024-04-02 JP JP2024059450A patent/JP7681151B2/ja active Active
-
2025
- 2025-04-02 US US19/098,185 patent/US20250257135A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6847037B2 (ja) | 抗ｃｄ７３抗体とａ２ａ受容体阻害薬とを含む併用治療薬及びその使用 | |
| JP2023115329A (ja) | 細胞傷害誘導治療剤 | |
| TWI920354B (zh) | 抗ｃｃｒ８抗體 | |
| US20230096030A1 (en) | Bispecific antibodies against cd9 and cd7 | |
| CN112703012A (zh) | 治疗癌症的方法 | |
| EA034921B1 (ru) | Модуляция стимулирующих и нестимулирующих миелоидных клеток | |
| KR20180012864A (ko) | Cd38과 특이적으로 결합하는 항체에 의한 고형 종양의 면역 조절 및 치료 | |
| KR20210075090A (ko) | Gm-csf 길항제를 이용한 면역요법-관련 독성의 치료 방법 | |
| CN116096756A (zh) | 针对ilt2的抗体及其用途 | |
| JP2026076334A (ja) | グリピカン３を標的とするキメラ抗原受容体を用いて癌を治療する組成物及び方法 | |
| CN114258401B (zh) | 对cd38具有特异性的抗体及其用途 | |
| CN113748132B (zh) | 抗trem1抗体和相关方法 | |
| US20210230262A1 (en) | Methods of treating immunotherapy-related toxicity using a gm-csf antagonist | |
| CN119317643A (zh) | 靶向新型肿瘤特异性抗原的骨髓病症和急性白血病的治疗 | |
| TW202515608A (zh) | Ｉｌ—１８ｂｐ拮抗抗體及其於癌症治療之單一療法及組合療法的用途 | |
| JP2022512544A5 (cg-RX-API-DMAC10.html) | ||
| JP2024534550A5 (cg-RX-API-DMAC10.html) | ||
| CN119161482A (zh) | 新颖抗体和核苷酸序列及其用途 | |
| RU2021108970A (ru) | Новые антитела и нуклеотидные последовательности и их применение | |
| CN114616245B (zh) | 一种抗cd38的抗体及其用途 | |
| CN116178546B (zh) | 一种多功能重组抗体及其制备方法和应用 | |
| CN115724979B (zh) | 一种多功能重组抗体及其制备方法和应用 | |
| CN115466329B (zh) | 一种抗pd-1人源化抗体及其应用 | |
| CN114127118B (zh) | 一种分离的抗原结合蛋白及其应用 | |
| Gokcen | Development of an MSC-based immune checkpoint inhibiting cell therapy |